Presented August News Today

Observational registry data from Sweden showed a significant link between SGLT2 inhibitor use at the time of an MI in people with type 2 diabetes and fewer all-cause deaths in 1-year follow-up.

Myocardial performance index, a heart-function metric derived from echo findings, significantly boosted the ability to predict incident CVD, especially heart failure, in people with type 1 diabetes.

The guideline task force says STEMI and non-ST elevation ACS represent a spectrum, and after the initial triage and management decisions, most of the remaining care follows a common pathway.

Results of the DANPACE II randomized trial refute the theory that slower pacing can reduce the risk of atrial fibrillation in patients with sinus node dysfunction.

Endocarditis can present with many different clinical scenarios, so making the diagnosis can be challenging, says a co-chair of newly issued European guidelines for managing this disease.

Patients resuscitated after cardiac arrest without ST elevation had the same survival if they were transported to the nearest hospital emergency department or a cardiac arrest center, in the UK ARREST trial.

In the ADVENT trial, pulsed field ablation, a new technology for terminating drug-refractory paroxysmal AF, was noninferior to conventional thermal ablation but had potential advantages.

The largest ever study of IV iron supplementation in patients with heart failure failed to meet a new rigorous definition of significance, and the results were generally regarded as disappointing.

New ESC guidelines recommend using both an SGLT2 inhibitor and a GLP-1 receptor agonist simultaneously to treat people with type 2 diabetes and established cardiovascular disease.

Among patients with atrial high-rate episodes detected by implantable devices, anticoagulation with edoxaban did not show a benefit but did increase bleeding risk in the NOAH-AFNET 6 trial.